12/20/2023 0 Comments Angiodynamics laser atherectomy![]() Left untreated, PAD can progress to cause life-threatening conditions, such as coronary artery disease and cerebrovascular disease 2. The prevalence of PAD for men and women increases with age and other factors, such as high blood pressure, smoking, diabetes, and high cholesterol 2. PAD is typically caused by the buildup of fatty plaque (known as atherosclerosis) in the arteries that carry blood to the extremities, and it affects over 200 million people around the globe, including 8.5 million people in the United States 1. ![]() Their strong support of the PATHFINDER I Registry, along with the enrollment of our first patient, represents a meaningful step toward achieving our shared goal of advancing the standard of care for patients with PAD and related conditions.” “Providers are showing an eagerness to enroll patients in the study and treat patients with our game-changing technology. “We believe that the solid-state laser technology utilized in the Auryon System is the future of atherectomy treatment,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. The PATHFINDER I Registry is a pilot study to evaluate the safety and efficacy of the Auryon Atherectomy System in the real-world treatment of de novo, re-stenotic, and in-stent restenosis (ISR) lesions in infrainguinal arteries of patients with Peripheral Artery Diseases (PAD). (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the enrollment of the first patient in the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05). In a realworld cohort of patient with complex disease, the Auryon laser had excellent freedom from TLR at 1 year.Īuryon laser femoropopliteal artery outcome retrospective target-lesion revascularization.AngioDynamics, Inc. The probability of freedom from TLR was 83.7%. ![]() Of 65 limbs treated, 2 (3.1%) had major amputation at 1 year. At 1 year, mortality occurred in 3/56 patients (5.4%). Distal embolization occurred in 1/65 procedures (1.5%). Drug-coated balloon usage was 47.1% Lutonix (BD/Bard), 27.1% In.Pact (Boston Scientific), and 1.4% both in all lesions treated. The majority of treated lesions were femoropopliteal (90.0%) of all procedures, 29.2% had 2 or more prior interventions. Embolic filters were used in 26/65 procedures (40%). Stenting was performed in 24/70 lesions (34.3%), with 11/70 (15.7%) bailout procedures. Of the 70 lesions, 31.4% had severe calcification, 38.6% were chronic total occlusions, and 48.6% were de novo disease (in-stent restenosis, 29.6%). The mean age was 70.9 ± 10 years, with 66.1% males, 48.2% diabetics, and 25% demonstrating limb ischemia. Statistical differences were analyzed for ankle-brachial index (ABI) between baseline and 1 year.Ī total of 56 patients (65 procedures, 70 lesions) were enrolled. Kaplan-Meier survival analysis was performed to estimate the freedom from TLR rate following index procedure. Secondary endpoints included unplanned major amputation and total mortality. TLR rates were obtained from medical record review of patients enrolled in the study who had completed office visit follow-up at 1 year. ![]() We present the TLR rate at 1 year in the same cohort of patients. There was no TLR seen at 6-month follow-up. The Auryon SCE was a retrospective study that evaluated the outcomes of all comers treated with the Auryon laser for infrainguinal arterial disease. In this study, we present the 1-year outcomes of the Auryon SCE study on TLR in all comers at a single center. The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the EX-PAD-03 investigational device exemption study and the Auryon single-center experience (SCE) in treating infrainguinal arteries. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |